News headlines about Inogen (NASDAQ:INGN) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Inogen earned a news impact score of 0.08 on Accern’s scale. Accern also gave news coverage about the medical technology company an impact score of 45.863970304669 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- Inogen, Inc. – Value Analysis (NASDAQ:INGN) : August 19, 2017 (finance.yahoo.com)
- Cramer's lightning round: Don't touch this pharma play (finance.yahoo.com)
- Inogen, Inc (INGN) Director Sells $1,283,380.00 in Stock (americanbankingnews.com)
- Cramer’s lightning round: Don’t touch this pharma play (finance.yahoo.com)
Several research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 8th. Zacks Investment Research cut shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Stifel Nicolaus lifted their target price on shares of Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a research note on Wednesday, May 10th. Needham & Company LLC lifted their target price on shares of Inogen from $96.00 to $108.00 and gave the company a “strong-buy” rating in a research note on Friday, June 9th. Finally, J P Morgan Chase & Co lifted their price target on shares of Inogen to $102.00 and gave the company an “overweight” rating in a report on Monday, June 26th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. Inogen currently has an average rating of “Buy” and a consensus price target of $91.60.
Shares of Inogen (INGN) opened at 93.96 on Friday. The stock has a 50 day moving average of $94.32 and a 200-day moving average of $83.24. Inogen has a 12-month low of $50.24 and a 12-month high of $98.33. The company has a market capitalization of $1.95 billion, a P/E ratio of 81.56 and a beta of 1.01.
Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.10. The firm had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The company’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period last year, the firm posted $0.25 earnings per share. Equities research analysts forecast that Inogen will post $1.21 EPS for the current year.
In related news, insider Scott Wilkinson sold 23,437 shares of the firm’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $88.06, for a total transaction of $2,063,862.22. Following the completion of the sale, the insider now directly owns 54,088 shares in the company, valued at $4,762,989.28. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Heath Lukatch sold 9,000 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $88.52, for a total transaction of $796,680.00. Following the sale, the director now owns 7,246 shares of the company’s stock, valued at $641,415.92. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 97,404 shares of company stock valued at $8,817,832. 5.31% of the stock is owned by company insiders.
About Inogen
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
